Stock Overview
Charles River Laboratories (CRL)
NYSE · Healthcare · Diagnostics & Research
Charles River Laboratories is a Healthcare company with a market capitalization of $10.39B.
Market Cap
$10.39B
Forward P/E
19.4
Price/Sales
2.6
Price/Book
3.5
EV/EBITDA
45.6
Beta
1.45
EPS (TTM)
$-3.71
Profit Margin
-4.6%
ROE
-5.9%
52W High
$228.88
52W Low
$144.26
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Revenue
$4.02B
Gross Profit
$1.23B
Operating Income
$507.84M
Net Income
-$144.34M
Free Cash Flow
$518.49M
Total Debt
$2.17B
Cash & Equivalents
$213.77M
Shareholder Equity
$3.16B
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $-0.30 | $0.91 | -133.0% |
| Q4 2025 | February 18, 2026 | $2.39 | $2.35 | +1.7% |
| Q3 2025 | November 5, 2025 | $2.43 | $2.34 | +3.9% |
| Q2 2025 | August 6, 2025 | $3.12 | $2.55 | +22.4% |
| Q1 2025 | May 7, 2025 | $2.34 | $2.07 | +13.0% |
| Q4 2024 | February 19, 2025 | $2.66 | $2.53 | +5.1% |
Other Diagnostics & Research Stocks
Frequently Asked Questions
What is Charles River Laboratories's market cap?
As of June 29, 2026, Charles River Laboratories (CRL) has a market capitalization of $10.39B.
Does Charles River Laboratories pay a dividend?
Charles River Laboratories does not currently pay a dividend.
What sector is CRL in?
Charles River Laboratories is in the Healthcare sector, specifically the Diagnostics & Research industry.
What was Charles River Laboratories's revenue?
In its latest reported fiscal year (ending December 31, 2025), Charles River Laboratories reported revenue of $4.02B and net income of -$144.34M.
Ask your own questions about CRL
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.